About Captozyme
Captozyme is a company based in Alachua (United States) founded in 2009 was acquired by Arranta Bio in November 2019. Captozyme has raised $3.4 million across 6 funding rounds from investors including HHS, Arranta Bio and Florida Institute. Captozyme offers products and services including RNA Manufacturing, Plasmid Manufacturing, Viral Vector Manufacturing, and ATMP Fill and Finish. Captozyme operates in a competitive market with competitors including Calliditas Therapeutics, Unicycive, Akebia Therapeutics, Alebund and Aurinia Pharmaceuticals, among others.
- Headquarter Alachua, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Captozyme Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.4 M (USD)
in 6 rounds
-
Latest Funding Round
$3.4 M (USD), Series A
Sep 23, 2016
-
Investors
HHS
& 2 more
-
Employee Count
Not available
-
Acquired by
Arranta Bio
(Nov 13, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Captozyme
Captozyme offers a comprehensive portfolio of products and services, including RNA Manufacturing, Plasmid Manufacturing, Viral Vector Manufacturing, and ATMP Fill and Finish.
Manufactures RNA therapies for pharmaceutical applications.
Produces plasmid DNA for biologics development.
Handles production of viral vectors for gene therapies.
Provides finishing services for advanced therapy medicinal products.
People of Captozyme
Unlock access to complete
Unlock access to complete
Funding Insights of Captozyme
Captozyme has successfully raised a total of $3.4M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $3.4 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Captozyme
Captozyme has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Arranta Bio and Florida Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Support is provided for Florida's technology ventures and innovation.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Developer of therapeutics for microbiome based diseases
|
Locked | Locked | Locked |
Investor details for Captozyme
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Captozyme
Investment portfolio details for Captozyme
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Captozyme
Detailed financials for Captozyme
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Captozyme Comparisons
Peer comparison for Captozyme
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Captozyme
Captozyme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Unicycive, Akebia Therapeutics, Alebund and Aurinia Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Small molecule therapies for kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| Locked | Locked | Locked |
Therapeutics for various kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
|
| Locked | Locked | Locked |
Therapeutics for renal diseases are developed and launched by Renalys.
|
Detailed competitors of Captozyme
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Captozyme
Complete news archive for Captozyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Captozyme
Captozyme was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Captozyme is headquartered in Alachua, United States. It is registered at Alachua, Florida, United States.
Captozyme is a funded company, having raised a total of $3.4M across 6 funding rounds to date.
Captozyme is a preclinical stage biotechnology company focussed on developing enzyme-based products for the dietary management of kidney stones and hyperoxaluria. It is developing its programs which enhance foods to reduce intake of oxalate which are the building block of up to 75 of all kidney stones. It claims that its enzymes removes oxalate from different food products and can also be added directly to your food to control and balance your oxalate intake. It is also planning to develop a product pipeline for hyperoxaluria.
Captozyme's top competitors include Calliditas Therapeutics, Akebia Therapeutics and Gennova.
Captozyme offers RNA Manufacturing, Plasmid Manufacturing, Viral Vector Manufacturing, and ATMP Fill and Finish.
Captozyme has 3 investors. Key investors include HHS, Arranta Bio, and Florida Institute.